Your browser doesn't support javascript.
loading
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Willis, Sophie E; Winkler, Claudia; Roudier, Martine P; Baird, Tarrion; Marco-Casanova, Paola; Jones, Emma V; Rowe, Philip; Rodriguez-Canales, Jaime; Angell, Helen K; Ng, Felicia S L; Waring, Paul M; Hodgson, Darren; Ledermann, Jonathan A; Weberpals, Johanne I; Dean, Emma; Harrington, Elizabeth A; Barrett, J Carl; Pierce, Andrew J; Leo, Elisabetta; Jones, Gemma N.
Afiliação
  • Willis SE; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Winkler C; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Roudier MP; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Baird T; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Marco-Casanova P; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Jones EV; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Rowe P; GMD, Oncology R&D, AstraZeneca, Macclesfield, UK.
  • Rodriguez-Canales J; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Angell HK; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Ng FSL; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Waring PM; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Hodgson D; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.
  • Ledermann JA; Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
  • Weberpals JI; Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Dean E; Clinical, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Harrington EA; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Barrett JC; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Pierce AJ; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Leo E; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Jones GN; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK. gemma.jones@astrazeneca.com.
Br J Cancer ; 125(12): 1666-1676, 2021 12.
Article em En | MEDLINE | ID: mdl-34663950
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dano ao DNA / Proteínas Nucleares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dano ao DNA / Proteínas Nucleares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article